<DOC>
	<DOCNO>NCT03039751</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy catheter mediate endocardial adenovirus-mediated vascular endothelial growth factor-D ( AdVEGF-D ) regenerative gene transfer patient refractory angina revascularisation perform .</brief_summary>
	<brief_title>Adenovirus Vascular Endothelial Growth Factor D ( AdvVEGF-D ) Therapy Treatment Refractory Angina Pectoris</brief_title>
	<detailed_description>Study overview : The purpose study evaluate safety efficacy catheter mediate AdVEGF-D regenerative gene transfer patient refractory angina revascularisation perform . Primary objective : To test efficacy therapy improve functional capacity use 6 minute walk test 6 month follow-up improvement symptom assess Canadian Cardiovascular Society ( CCS ) class . Secondary objective : Efficacy gene transfer increase improve functional capacity use 6 minute walk test improvement symptom assess CCS class 12 month well increase myocardial perfusion assess 6 month gene transfer . In addition , 6 12 month timepoints , improvement quality life ( QoL ) , use angina pectoris medication , major adverse cardiac event related coronary artery disease ( cardiovascular death , myocardial infarction , stroke , revascularization hospital admission due coronary artery disease ) combine endpoint ( Major Adverse Cardiac Events , MACE ) evaluate . Study design : ReGenHeart randomize , double-blinded , placebo-controlled multicentre phase II study conduct 6 center . The study evaluate efficacy safety catheter mediate endocardial AdVEGF-D regenerative gene transfer 180 patient angina pectoris equivalent symptom despite optimal medical therapy suitable candidate coronary revascularization coronary artery bypass grafting ( CABG ) percutaneous coronary intervention ( PCI ) ( refractory angina patient ) . Study population : 180 patient recruit six center 2 year . The patient select trial basis medical history , general status , laboratory analysis , coronary angiogram 6-minute walking test . Patients CCS 2-3 angina pectoris despite optimal medical therapy eligible coronary angioplasty bypass operation due diffuse coronary stenosis , small coronary vessel , repeat revascularization high risk operation , include . The number subject recruit randomized trial 180 ( 2:1 ratio treatment control group ) . Investigational drug product : First generation replication-deficient AdVEGF-D produce 293 cell inject ten site endocardium . The dose 1x1011 vp total volume 2 ml ( 10 time 0.2 ml ) use . Control patient treat operate exactly way except placebo ( buffer solution without gene ) injection myocardium use .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>informed consent sign age &gt; 30 &lt; 85 year significant angina pectoris ( CCS 23 ) despite optimal medication significant stenosis ( &gt; 60 % ) coronary angiography ( &lt; 6 month ) contraindication CABG PCI due diffuse distal stenosis , chronic total occlusion , vessel difficult anatomy , stenosis severe calcification stenosis small vessel ( &lt; 2.5 mm ) ) angina pectoris equivalent symptom 6minute walk exercise test leave ventricle wall &gt; 8 mm detect transthoracic echocardiography magnetic resonance imaging ( treatment area ) woman fertile age diabetes mellitus severe complication diabetic retinopathy nephropathy clinically significant anemia ( hemoglobin count &lt; 120 mg/l male , &lt; 110 mg/l female ; hematocrit &lt; 0.36 ) , leukopenia ( bleukocyte count &lt; 3.0x109/l ) , leukocytosis ( bleukocyte count &gt; 12.0x109/l ) thrombocytopenia ( bthrombocyte count &lt; 100x109/l ) renal insufficiency ( Pcreatinine &gt; 160 mg/l ) liver insufficiency ( Palanine aminotransferase Palkaline phosphatase 2 x normal ) haematuria unknown origin severe hypertension ( systolic blood pressure &gt; 200 mmHg diastolic blood pressure &gt; 110 mmHg ) significant hypotension ( systolic blood pressure &lt; 90 mmHg ) significant obesity ( Body Mass Index &gt; 35 ) acute infection immunosuppressive medication significant impairment leave ventricular function ( ejection fraction &lt; 25 % echocardiography ) symptomatic congestive heart failure ( New York Heart Association class 34 ) haemodynamically significant ( grade 34/4 ) aortic mitral regurgitation heart disease need surgery recent ( &lt; 6 week ) acute coronary syndrome myocardial infarction , PCI CABG , stroke transient ischemic attack ( TIA ) current suspect malignancy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>